BOSTON and ROLLE, Switzerland — October 16, 2025 — Leads & Copy — SOPHiA GENETICS (Nasdaq: SOPH) has launched SOPHiA DDM™ Digital Twins, an AI-driven research technology creating virtual patient representations for better oncology treatment decisions.
The technology uses patient-unique data to simulate treatment responses and disease trajectories in real-time. Dr. Pierre Heudel from Centre Léon Bérard notes its potential for in silico experimentation, while Dr. Clara Montagut from Hospital del Mar highlights its transformative impact on future care.
SOPHiA DDM™ Digital Twins leverages a global patient case network, enhancing clinical decision-making by breaking down geographic barriers. Dr. Ernest Nadal of the Catalan Institute of Oncology sees it as a step towards precision medicine.
Dr. Mariano Provencio Pulla from Puerta de Hierro University Hospital hails the Digital Twins concept as a breakthrough, crucial for maximizing clinical care advancements, especially in pre-surgical immunotherapy for lung cancer patients.
The AI-powered tool continuously evolves with new data, improving accuracy and research capabilities. It also generates synthetic data to explore additional therapeutic paths.
Jurgi Camblong, Ph.D., Co-Founder & CEO of SOPHiA GENETICS, emphasizes the tool’s ability to accelerate research and sharpen clinical decisions, making data-driven medicine a global standard.
Digital Twins is launching on the SOPHiA DDMTM Platform for lung cancer, with more cancer types coming soon. Key features include personalized treatment insights, toxicity and cost avoidance, and global knowledge impact.
For more information, contact support@sophiagenetics.com.
Source: SOPHiA GENETICS
